Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $2.7 million.

  • Whitehawk Therapeutics' Share-based Compensation rose 629.64% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 2279.27%. This contributed to the annual value of $10.8 million for FY2024, which is 932.74% down from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Share-based Compensation of $2.7 million as of Q3 2025, which was up 629.64% from $3.1 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Share-based Compensation peaked at $3.6 million during Q1 2024, and registered a low of $36000.0 during Q1 2021.
  • For the 5-year period, Whitehawk Therapeutics' Share-based Compensation averaged around $2.2 million, with its median value being $2.7 million (2025).
  • In the last 5 years, Whitehawk Therapeutics' Share-based Compensation tumbled by 8900.65% in 2021 and then surged by 563076.92% in 2022.
  • Whitehawk Therapeutics' Share-based Compensation (Quarter) stood at $1.4 million in 2021, then skyrocketed by 107.52% to $2.9 million in 2022, then increased by 8.4% to $3.1 million in 2023, then plummeted by 40.41% to $1.9 million in 2024, then skyrocketed by 46.6% to $2.7 million in 2025.
  • Its Share-based Compensation stands at $2.7 million for Q3 2025, versus $3.1 million for Q2 2025 and $1.7 million for Q1 2025.